BridgeBio
BBIO
$65.35
+0.48%
BridgeBio Pharma is a commercial-stage biotechnology company focused on discovering, developing, and delivering transformative treatments for patients with genetic diseases, with a late-stage pipeline spanning Mendelian disorders, oncology, and gene therapy. Its lead commercial asset, Attruby (acoramidis), is an orally administered transthyretin stabilizer approved for transthyretin amyloid cardiomyopathy (ATTR-CM), positioning the company as a direct competitor to Pfizer's tafamidis and Alnylam's RNAi-based therapies in a multi-billion-dollar market. The current investor narrative centers on the rapid commercial ramp of Attruby — product revenue reached $222.4 million in Q2 2026, roughly doubling year-over-year — alongside positive Phase 3 data in achondroplasia (dwarfism) that positions the company for an FDA filing, both of which have driven analyst enthusiasm and a "strong buy" consensus. However, the debate is increasingly two-sided: bulls point to a 94% gross margin and a pipeline with multiple near-term catalysts, while bears highlight persistent quarterly net losses exceeding $150 million, deeply negative free cash flow, and a stock that has fallen roughly 24% over the past three months despite the fundamental progress.…
BBIO
BridgeBio
$65.35
Related headlines
Investment Opinion: Should I buy BBIO Today?
We assign a Hold rating on BBIO, balancing the impressive 101% YoY revenue growth and 93.24% gross margin against a deeply negative free cash flow of -$592 million and a premium 30x sales valuation. The analyst consensus is 'strong buy' with an average target of $109.05, implying 66.9% upside, but the recent 24% three-month decline and relative underperformance suggest the market is pricing in execution risks. The core thesis is that Attruby's commercial ramp is real and substantial, but the company must demonstrate a path to profitability without dilutive financing to justify a higher rating.
Supporting evidence includes Q2 2026 revenue of $222.44 million (up 101.18% YoY), a gross margin of 93.24%, and a sequential revenue growth trend from $154 million to $194 million to $222 million. The forward EPS estimate of $10.35 implies a forward PE of just 6.3x, reflecting expectations of a dramatic profitability inflection. However, the TTM PS of 30.05x is well above the 4x-8x range for profitable biotech peers, and the negative debt-to-equity of -1.31 highlights balance sheet fragility. The implied upside to the average target is 66.9%, but this gap may reflect stale targets rather than undervaluation.
The biggest risks are the cash burn trajectory, competitive pressures in ATTR-CM, and the need for additional capital. The rating would upgrade to Buy if Q3 revenue exceeds $250 million and free cash flow burn moderates below $150 million, or if the company secures non-dilutive financing. It would downgrade to Sell if revenue growth decelerates below 50% YoY or if cash reserves fall below $200 million without a clear path to profitability. Relative to its own history, the PS ratio has compressed from 97.85x in Q4 2025 to 30.05x now, but it remains elevated versus peers, suggesting the stock is fairly valued at best, with downside risk if growth disappoints.
Sign up to view all
BBIO 12-Month Price Forecast
BridgeBio presents a compelling growth story with Attruby's rapid commercial ramp, but the financial risks are substantial. The company's ability to achieve profitability without dilutive financing is the key swing factor. The analyst consensus is overwhelmingly bullish, yet the stock's technical weakness and premium valuation suggest the market is pricing in execution risks. We would upgrade to bullish if Q3 revenue exceeds $250 million and cash burn moderates, or downgrade to bearish if revenue growth slows below 50% or cash reserves fall below $200 million. The risk/reward is balanced at current levels, favoring a wait-and-see approach until clearer profitability signals emerge.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on BridgeBio's 12-month outlook, with a consensus price target around $109.05 and implied upside of +66.9% versus the current price.
Average Target
$109.05
0 analysts
Implied Upside
+66.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$80 - $156
Analyst target range
Coverage is robust, with 21 analysts following BridgeBio and a consensus recommendation of "strong buy" (recommendation mean of 1.45 on a 1–5 scale where 1 is a strong buy). The average price target is $109.05, implying approximately 66.9% upside from the current price of $65.35 — an unusually large gap that reflects either significant undervaluation or stale targets that have not yet been revised downward to reflect the recent 24% three-month decline. The consensus EPS estimate of $10.35 (range of $8.91 to $12.89) and revenue estimate of $4.71 billion (range of $4.20 billion to $5.60 billion) imply the analyst community expects a dramatic profitability inflection, with revenue roughly 5x the current annualized run-rate.
The target range spans $80.00 to $156.00 — a wide $76 spread that signals high uncertainty and divergent views on Attruby's peak sales potential and pipeline value. The high target of $156.00 likely assumes rapid Attruby share capture in ATTR-CM, successful achondroplasia approval and launch, and multiple pipeline readouts, while the low target of $80.00 — still 22.4% above the current price — prices in slower commercial uptake and continued cash burn requiring dilution. Institutional ratings show a uniformly constructive tone, with recent actions from HC Wainwright (Buy, reiterated September 10), Mizuho (Outperform, September 1), JP Morgan (Overweight, August 12), Morgan Stanley (Overweight, August 11), and B of A (Buy, August 11) all maintaining positive ratings without downgrades. Notably, no firm has moved to a Hold or Sell despite the sharp price decline, suggesting analysts view the pullback as a buying opportunity rather than a fundamental deterioration — though the persistent gap between the $109 average target and the $65 price will need to close either through price recovery or target reductions.
Bulls vs Bears: BBIO Investment Factors
The bull case rests on Attruby's explosive revenue growth (101% YoY), exceptional gross margins (93.24%), and a robust pipeline with near-term catalysts, supported by a 'strong buy' consensus and a $109.05 average target. The bear case highlights the stark reality of -$592 million TTM free cash flow, a $504 million quarterly cash decline, and a 30x sales valuation that prices in flawless execution. Currently, the bear evidence carries more weight because the cash burn and negative equity create tangible financing risk, while the technical downtrend and relative underperformance suggest the market is skeptical of the growth narrative. The single most important tension is whether Attruby's revenue ramp can scale fast enough to achieve profitability before the company requires dilutive capital; if Q3 revenue exceeds $250 million and cash burn moderates, the bull case strengthens considerably, but a miss could trigger a sharp de-rating.
Bullish
- Attruby revenue doubling year-over-year: Q2 2026 revenue reached $222.44 million, up 101.18% from $110.57 million in Q2 2025, with sequential growth from $154.18 million in Q4 2025 to $194.52 million in Q1 2026. This trajectory confirms rapid commercial adoption of Attruby in the multi-billion-dollar ATTR-CM market.
- Exceptional gross margins near 94%: Q2 2026 gross margin was 93.24%, consistent with 94.64% in Q1 2026 and 90.0% in Q4 2025. This best-in-class profitability profile provides substantial operating leverage as revenue scales.
- Strong analyst consensus with 67% upside: 21 analysts rate BBIO a 'strong buy' (mean 1.45), with an average price target of $109.05, implying 66.9% upside from the current $65.35. No downgrades have occurred despite the recent 24% three-month decline.
- Pipeline catalysts in achondroplasia and beyond: Positive Phase 3 data in achondroplasia positions BridgeBio for an FDA filing in 2026, potentially adding a second commercial asset. The company also has late-stage programs in oncology and gene therapy, diversifying future revenue.
Bearish
- Deeply negative free cash flow and cash burn: TTM free cash flow is -$592.12 million, with Q2 2026 alone burning $223.78 million. Cash fell from $882.02 million to $377.71 million in one quarter, raising the risk of dilutive financing if the burn rate persists.
- Persistent net losses despite revenue growth: Q2 2026 net loss was $152.22 million (net margin -68.43%), with operating loss of $107.08 million and EBITDA of -$136.63 million. Profitability remains elusive as operating expenses totaled $314.47 million.
- Premium valuation at 30x sales: BBIO trades at a trailing PS of 30.05x and EV/Sales of 21.56x, well above the 4x-8x range for profitable commercial-stage biotech peers. This premium leaves little room for execution missteps.
- Negative equity and high leverage: Debt-to-equity is -1.31 due to negative shareholders' equity, and the reported ROE of 35.12% is an artifact of that negative base. The balance sheet offers limited cushion for further losses.
BBIO Technical Analysis
BridgeBio is in a medium-term downtrend that has partially reversed a strong prior-year advance. The stock is up 19.27% over the trailing twelve months, but that gain masks a sharp deterioration: the shares are down 16.47% year-to-date and 12.39% over six months, and at $65.35 the stock sits at roughly 30.9% of its 52-week range (52-week low of $52.75, 52-week high of $93.415). That positioning — closer to the bottom than the top of the annual band — suggests the market has been de-rating the name even as revenue scales, a classic "show-me" setup where execution must re-earn multiple expansion. The 52-week high of $93.415 was set during the July 2026 spike (the stock closed at $90.17 on July 9), and the subsequent 30% drawdown from that peak defines the current corrective phase.
Short-term momentum is decisively negative and diverging from the longer-term trend. The stock is down 14.10% over the past month and 23.91% over three months, versus a 1-year gain of 19.27% — a clear deceleration that signals the July rally has fully unwound. Relative strength confirms the underperformance: BBIO trails SPY by 16.22 percentage points over one month, 27.04 points over three months, and 30.64 points year-to-date, even though it modestly outperformed SPY by 3.27 points over the full year. The most recent price action shows stabilization attempts — the stock bounced from $65.04 to $65.35 on the latest day (+0.48%) on volume of 1.85 million shares — but with a short ratio of 10.61, meaning more than ten days of average volume are sold short, there is meaningful bearish positioning that could fuel a squeeze if a catalyst emerges.
Key technical levels are well defined. Support sits at the 52-week low of $52.75, roughly 19% below the current $65.35 price; a breakdown there would signal capitulation and likely open a deeper retracement. Resistance is anchored at the 52-week high of $93.415, about 43% above current levels, with intermediate resistance likely around the $76–$80 zone where the stock consolidated in August and September. The beta of 0.972 indicates the stock moves roughly in line with the broader market, which is unusually low for a clinical-stage biotech and suggests idiosyncratic, company-specific factors (Attruby launch trajectory, pipeline data, financing needs) are driving the price rather than macro risk appetite. The maximum drawdown of -27.87% over the period underscores that position sizing should account for sharp, catalyst-driven moves in either direction.
Beta
0.97
0.97x market volatility
Max Drawdown
-27.9%
Largest decline past year
52-Week Range
$53-$93
Price range past year
Annual Return
+19.3%
Cumulative gain past year
| Period | BBIO Return | S&P 500 |
|---|---|---|
| 1m | -14.1% | +1.9% |
| 3m | -23.9% | +3.9% |
| 6m | -12.4% | +12.1% |
| 1y | +19.3% | +19.2% |
| ytd | -16.5% | +14.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BBIO Fundamental Analysis
BridgeBio's revenue trajectory has inflected dramatically with the Attruby launch. Q2 2026 revenue reached $222.44 million, up 101.18% year-over-year from $110.57 million in Q2 2025, and up sequentially from $194.52 million in Q1 2026 and $154.18 million in Q4 2025. The revenue mix is overwhelmingly product-driven: product revenue of $222.44 million dwarfs license and service revenue of $5.80 million and royalty revenue of $15.43 million, confirming that Attruby's commercial ramp is the entire growth story. The sequential progression from $154 million to $194 million to $222 million implies roughly 14% quarter-over-quarter growth, which, if sustained, would annualize well above the $4.7 billion consensus revenue estimate — though the deceleration in the growth rate from the prior year's explosive base bears watching.
Profitability remains the central concern despite exceptional gross margins. Q2 2026 gross margin was 93.24% (gross profit of $207.39 million on $222.44 million revenue), consistent with the 94.64% in Q1 2026 and 90.0% in Q4 2025 — a best-in-class profile typical of a successful branded pharmaceutical. However, the company posted a net loss of $152.22 million in Q2 2026 (net margin of -68.43%), an operating loss of $107.08 million (operating margin of -48.14%), and EBITDA of -$136.63 million. The loss is driven by heavy operating expenses of $314.47 million, including $149.45 million in R&D and $186.26 million in SG&A, reflecting the cost of commercial build-out and pipeline advancement. Encouragingly, the net loss narrowed from $164.04 million in Q1 2026 and $197.24 million in Q4 2025, suggesting operating leverage is beginning to materialize as revenue scales against a relatively fixed cost base.
The balance sheet and cash flow profile present the most significant risk. Free cash flow is deeply negative at -$592.12 million on a trailing-twelve-month basis, with Q2 2026 free cash flow of -$223.78 million and operating cash flow of -$223.33 million, and cash fell from $882.02 million at the start of Q2 to $377.71 million at quarter-end — a $504.31 million net cash decline in a single quarter. The current ratio of 2.62 provides adequate near-term liquidity, but the debt-to-equity ratio of -1.31 reflects negative shareholders' equity, and the reported ROE of 35.12% is a statistical artifact of that negative equity base rather than genuine profitability. With capital expenditures minimal at $443,000, the cash burn is almost entirely operational, and the company's ability to fund its pipeline without dilutive financing depends on Attruby's revenue ramp continuing to outpace spending growth.
Quarterly Revenue
$222440000.0B
2026-06
Revenue YoY Growth
+101.2%
YoY Comparison
Gross Margin
93.2%
Latest Quarter
Free Cash Flow
$-592121000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BBIO Overvalued?
Because BridgeBio reported negative net income (Q2 2026 net loss of $152.22 million) and negative EBITDA (-$136.63 million), the trailing PE ratio of -20.18 and EV/EBITDA of -25.49 are not meaningful. The appropriate primary metric is therefore the price-to-sales ratio: BBIO trades at a trailing PS of 30.05x and an EV/Sales of 21.56x. The forward PE of 2,378.96x is technically positive but economically meaningless at this stage, reflecting the market's expectation that earnings will only just cross into positive territory; the forward EPS estimate of $10.35 implies a forward PE of roughly 6.3x on that estimate, a dramatic compression that captures the market's bet on imminent, steep profitability inflection.
On a peer basis, BridgeBio's 30.05x trailing PS and 21.56x EV/Sales represent a substantial premium to the broader biotechnology sector, where profitable commercial-stage companies typically trade in the 4x–8x sales range and even high-growth rare-disease peers rarely exceed 15x. The premium is partially justified by the 101.18% year-over-year revenue growth and 93.24% gross margin, but it also prices in flawless Attruby execution and pipeline success. The negative PB ratio of -7.27 and PCF ratio of -33.83 are not usable for comparison given negative equity and cash flow, reinforcing that sales-based metrics are the only viable lens at present.
Historically, BridgeBio's PS ratio has compressed dramatically as revenue has scaled: from 97.85x in Q4 2025 to 74.36x in Q1 2026 to 65.56x in Q2 2026 on the historical ratios data, and now to 30.05x on the current trailing basis. This rapid multiple compression reflects revenue growth outpacing share price appreciation — a mathematically healthy dynamic that suggests the stock is getting cheaper on fundamentals even as the price falls. However, the current 30.05x remains elevated versus the company's own pre-commercial history only in absolute terms; the key question is whether the multiple can continue compressing toward peer levels through revenue growth rather than price decline, which hinges entirely on the durability of Attruby's launch trajectory.
PE
-20.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-25.5x
Enterprise Value Multiple
Investment Risk Disclosure
BridgeBio faces significant financial and operational risks. The company burned $223.78 million in free cash flow in Q2 2026 alone, with TTM free cash flow at -$592.12 million, and cash reserves plummeted from $882.02 million to $377.71 million in a single quarter. With debt-to-equity at -1.31 and negative shareholders' equity, the balance sheet offers little cushion, and the current ratio of 2.62, while adequate for now, could deteriorate rapidly if losses persist. The company's entire growth story depends on Attruby, which generated $222.44 million in Q2 2026 product revenue; any slowdown in its adoption or competitive pressure from Pfizer's tafamidis or Alnylam's RNAi therapies would severely impact revenue and delay profitability.
Market and competitive risks are substantial. The stock trades at a premium valuation of 30.05x trailing sales and 21.56x EV/Sales, leaving it vulnerable to multiple compression if growth decelerates or if peers trade at lower multiples. The beta of 0.972 indicates the stock moves roughly in line with the broader market, but its idiosyncratic risks—clinical trial outcomes, regulatory decisions, and financing needs—dominate. Recent news highlights competitive threats in achondroplasia, with BioMarin's royalty deal and potential oral rivals, while the broader biotech sector remains sensitive to interest rate expectations and drug pricing reforms. The short ratio of 10.61 signals significant bearish positioning, which could amplify downside if a catalyst disappoints.
The worst-case scenario involves a combination of slowing Attruby sales, a delay or failure in the achondroplasia FDA filing, and a need for dilutive financing. In this scenario, the stock could retest its 52-week low of $52.75, representing a 19.3% decline from the current $65.35. If the bear case fully materializes, including a revenue miss and cash burn exceeding $250 million per quarter, the stock could fall to the analyst low target of $80.00—though that is above the current price, suggesting the analyst low may be stale. A more realistic downside, given the negative sentiment, could see the stock drop to the $52-$55 range, a loss of 16-19% from current levels, with further downside if financing occurs at distressed prices.
FAQ
The most severe risk is financial: TTM free cash flow is -$592 million, and cash fell by $504 million in Q2 2026 alone, raising the specter of dilutive financing. Competitive risk is also high, as Pfizer and Alnylam compete in ATTR-CM, and BioMarin's royalty deal highlights threats in achondroplasia. Macro risk is moderate given the beta of 0.972, but biotech sentiment is sensitive to interest rates. Company-specific risk includes pipeline failures and regulatory delays, with the achondroplasia FDA filing a key near-term event. Ranked by severity: financial, competitive, regulatory, and macro.
Our 12-month forecast has a base case (50% probability) of $80-$109, assuming moderate revenue growth and narrowing losses. The bull case (30% probability) targets $109-$156 if Attruby accelerates and the pipeline delivers. The bear case (20% probability) sees $52-$80 if growth stalls and financing becomes dilutive. The most likely scenario is the base case, hinging on Attruby revenue reaching $3.5-$4.0 billion annualized and cash burn moderating. Analyst targets range from $80 to $156, with an average of $109.05, but these may be stale given the recent decline.
BBIO appears overvalued on traditional metrics, trading at 30.05x trailing sales and 21.56x EV/Sales, well above the 4x-8x range for profitable biotech peers. The forward PE of 2,378x is not meaningful, but the forward EPS estimate of $10.35 implies a forward PE of 6.3x, suggesting the market expects a sharp profitability inflection. Relative to its own history, the PS ratio has compressed from 97.85x in Q4 2025 to 30.05x now, but it remains elevated. The valuation implies the market is pricing in flawless execution of Attruby and pipeline success, leaving little margin for error.
BBIO is a high-risk, high-reward investment suitable for growth-oriented investors. The stock trades at $65.35, with a 'strong buy' consensus and an average target of $109.05, implying 66.9% upside. However, the company burns significant cash (-$592 million TTM) and faces a premium valuation at 30x sales. It could be a good buy for those who believe in Attruby's long-term potential and can tolerate volatility, but the downside risk to the 52-week low of $52.75 (-19%) is real. A more prudent approach may be to wait for evidence of moderating cash burn or a better entry point.
BBIO is more suitable for long-term investment, given its early commercial stage, high volatility (beta 0.972, max drawdown -27.87%), and no dividend. The company's growth story will take years to fully play out, with pipeline catalysts and profitability inflection expected beyond 2027. Short-term trading is risky due to binary events like FDA decisions and earnings, which can cause sharp moves. A minimum holding period of 2-3 years is recommended to allow for commercial ramp and pipeline maturation. Investors should size positions to withstand potential 30-40% drawdowns.